METHODS FOR TREATING DEGENERATIVE DISEASES/INJURIES
Invented is a method of treating degenerative diseases/injuries, in a mammal, including a human, in need thereof which comprises the administration of a therapeutically effective amount of a non-peptide TPO receptor agonist to such mammal.
1 . A method of treating gastrointestinal disease in a human in need thereof which comprises the in vivo administration of a therapeutically effective amount of a compound selected from
3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid,
or a pharmaceutically acceptable salt thereof, and
3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl,
or a pharmaceutically acceptable salt thereof;
to such human.
2 . A method of treating a disease selected from: inflammatory bowel disease, ulcerative colitis, Crohn's disease and Mucositis, in a human in need thereof which comprises the in vivo administration of a therapeutically effective amount of a compound selected from
3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid,
or a pharmaceutically acceptable salt thereof, and
3-{N′-[1-(3,4-dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2-hydroxy-3′-tetrazol-5-ylbiphenyl,
or a pharmaceutically acceptable salt thereof;
to such human.
3 . A method according to claim 2 wherein the compound is 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid or a pharmaceutically acceptable salt thereof.
4 . A method according to claim 2 wherein the compound is 3′-{N′-[1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1,5-dihydropyrazol-4-ylidene]hydrazino}-2′-hydroxybiphenyl-3-carboxylic acid bis-(monoethanolamine).
5 . A method according to claim 4 wherein the disease is inflammatory bowel disease.
6 . A method according to claim 4 wherein the disease is ulcerative colitis.
7 . A method according to claim 4 wherein the disease is Crohn's disease.
8 . A method according to claim 4 wherein the disease is Mucositis.
9 . A method according to claim 4 wherein the compound is administered orally.
10 . A method according to claim 4 wherein the compound is administered parenterally.
11 . A method according to claim 9 wherein the compound is administered in tablet form.
12 . A method according to claim 8 wherein the Mucositis is due to radiation.
13 . A method according to claim 11 wherein the tablet contains an amount from 0.05 to 3500 mg of active compound.
14 . A method according to claim 11 wherein the tablet contains an amount from 0.1 to 3000 mg of active compound.
15 . A method according to claim 11 wherein the tablet contains 20 mg of active compound.
16 . A method according to claim 5 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.
17 . A method according to claim 5 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.
18 . A method according to claim 5 wherein the compound is administered in a tablet that contains 20 mg of active compound.
19 . A method according to claim 6 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.
20 . A method according to claim 6 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.
21 . A method according to claim 6 wherein the compound is administered in a tablet that contains 20 mg of active compound.
22 . A method according to claim 7 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.
23 . A method according to claim 7 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.
24 . A method according to claim 7 wherein the compound is administered in a tablet that contains 20 mg of active compound.
25 . A method according to claim 8 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.
26 . A method according to claim 8 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.
27 . A method according to claim 8 wherein the compound is administered in a tablet that contains 20 mg of active compound.
28 . A method according to claim 8 wherein the compound is administered prior to radiation.
29 . A method according to claim 28 wherein the compound is administered in a tablet that contains an amount from 0.05 to 3500 mg of active compound.
30 . A method according to claim 28 wherein the compound is administered in a tablet that contains an amount from 0.1 to 3000 mg of active compound.
31 . A method according to claim 28 wherein the compound is administered in a tablet that contains 20 mg of active compound.